Protein engineering strategies for the development of viral vaccines and immunotherapeutics

FEBS Letters

Volumn 588, Issue 2, 2014, Pages 298-307

  Koellhoffer, Jayne F ^a   Higgins, Chelsea D ^a   Lai, Jonathan R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody engineering; Antiviral immunotherapy; Immunogen design

Indexed keywords

DENGUE VACCINE; DENGUE VACCINE 4E11; DENGUE VACCINE 4E5A; EPITOPE; GLYCOPROTEIN GP 41; HEMAGGLUTININ; MONOCLONAL ANTIBODY; NANOPARTICLE; NEUTRALIZING ANTIBODY; PALIVIZUMAB; SIALIC ACID; SIALIDASE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; BINDING AFFINITY; BINDING SITE; CROSS REACTION; DENGUE; DRUG POTENCY; EBOLA VIRUS; ENZYME CONFORMATION; ESCHERICHIA COLI; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; LIPID BILAYER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN ENGINEERING; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; X RAY CRYSTALLOGRAPHY;

ANTIBODY ENGINEERING; ANTIVIRAL IMMUNOTHERAPY; IMMUNOGEN DESIGN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; HUMANS; IMMUNOTHERAPY; PROTEIN ENGINEERING; VIRAL VACCINES;

EID: 84892373125     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.10.014     Document Type: Review

References (93)

1. D.B. Huang, J.J. Wu, and S.K. Tyring A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines J. Infect. 49 2004 179 209
2. S.A. Plotkin Correlates of protection induced by vaccination Clin. Vaccine Immunol. 17 2010 1055 1065
3. D.R. Burton Antibodies, viruses and vaccines Nat. Rev. Immunol. 2 2002 706 713
4. M.S. Miller, T.J. Gardner, F. Krammer, L.C. Aguado, D. Tortorella, C.F. Basler, and P. Palese Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis Sci. Transl. Med. 5 2013 198ra107
5. N. Khetsuriani, M.A. Pallansch, S. Jabirov, N. Saparova, M.S. Oberste, K. Wannemuehler, P. Ursu, S. Wassilak, and R. Martin Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010 Vaccine 31 2013 4911 4916
6. A. Takada, H. Ebihara, S. Jones, H. Feldmann, and Y. Kawaoka Protective efficacy of neutralizing antibodies against Ebola virus infection Vaccine 25 2007 993 999
7. M. Law, T. Maruyama, J. Lewis, E. Giang, A.W. Tarr, Z. Stamataki, P. Gastaminza, F.V. Chisari, I.M. Jones, R.I. Fox, J.K. Ball, J.A. McKeating, N.M. Kneteman, and D.R. Burton Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge Nat. Med. 14 2008 25 27
8. L. Hangartner, R.M. Zinkernagel, and H. Hengartner Antiviral antibody responses: the two extremes of a wide spectrum Nat. Rev. Immunol. 6 2006 231 243
9. T.J. Smith, E.S. Chase, T.J. Schmidt, N.H. Olson, and T.S. Baker Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon Nature 383 1996 350 354
10. D.T. Leung, F.C. Tam, C.H. Ma, P.K. Chan, J.L. Cheung, H. Niu, J.S. Tam, and P.L. Lim Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid J. Infect. Dis. 190 2004 379 386
11. H. Sakurai, R.A. Williamson, J.E. Crowe, J.A. Beeler, P. Poignard, R.B. Bastidas, R.M. Chanock, and D.R. Burton Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines J. Virol. 73 1999 2956 2962
12. M.D. Simek, W. Rida, F.H. Priddy, P. Pung, E. Carrow, D.S. Laufer, J.K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, J. Birungi, A. Pozniak, D.A. McPhee, O. Manigart, E. Karita, A. Inwoley, W. Jaoko, J. Dehovitz, L.G. Bekker, P. Pitisuttithum, R. Paris, L.M. Walker, P. Poignard, T. Wrin, P.E. Fast, D.R. Burton, and W.C. Koff Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm J. Virol. 83 2009 7337 7348
13. T. Maruyama, L.L. Rodriguez, P.B. Jahrling, A. Sanchez, A.S. Khan, S.T. Nichol, C.J. Peters, P.W. Parren, and D.R. Burton Ebola virus can be effectively neutralized by antibody produced in natural human infection J. Virol. 73 1999 6024 6030
14. J.M. Dias, A.I. Kuehne, D.M. Abelson, S. Bale, A.C. Wong, P. Halfmann, M.A. Muhammad, M.L. Fusco, S.E. Zak, E. Kang, Y. Kawaoka, K. Chandran, J.M. Dye, and E.O. Saphire A shared structural solution for neutralizing Ebolaviruses Nat. Struct. Mol. Biol. 18 2011 1424 1427
15. X. Qiu, J.B. Alimonti, P.L. Melito, L. Fernando, U. Stroher, and S.M. Jones Characterization of Zaire Ebolavirus glycoprotein-specific monoclonal antibodies Clin. Immunol. (Orlando Fla) 141 2011 218 227
16. S. Johnson, C. Oliver, G.A. Prince, V.G. Hemming, D.S. Pfarr, S.C. Wang, M. Dormitzer, J. O'Grady, S. Koenig, J.K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W.C. Hall, and J.F. Young Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus J. Infect. Dis. 176 1997 1215 1224
17. N. Prabhu, M. Prabakaran, H.T. Ho, S. Velumani, J. Qiang, M. Goutama, and J. Kwang Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection J. Virol. 83 2009 2553 2562
18. M.L. Azoitei, Y.E. Ban, J.P. Julien, S. Bryson, A. Schroeter, O. Kalyuzhniy, J.R. Porter, Y. Adachi, D. Baker, E.F. Pai, and W.R. Schief Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope J. Mol. Biol. 415 2012 175 192
19. M.L. Azoitei, B.E. Correia, Y.E. Ban, C. Carrico, O. Kalyuzhniy, L. Chen, A. Schroeter, P.S. Huang, J.S. McLellan, P.D. Kwong, D. Baker, R.K. Strong, and W.R. Schief Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold Science (New York, NY) 334 2011 373 376
20. K. Chakraborty, V. Durani, E.R. Miranda, M. Citron, X. Liang, W. Schleif, J.G. Joyce, and R. Varadarajan Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies Biochem. J. 399 2006 483 491
21. B.E. Correia, Y.E. Ban, M.A. Holmes, H. Xu, K. Ellingson, Z. Kraft, C. Carrico, E. Boni, D.N. Sather, C. Zenobia, K.Y. Burke, T. Bradley-Hewitt, J.F. Bruhn-Johannsen, O. Kalyuzhniy, D. Baker, R.K. Strong, L. Stamatatos, and W.R. Schief Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope Structure (London, England: 1993) 18 2010 1116 1126
22. S.M. Dennison, S.M. Stewart, K.C. Stempel, H.X. Liao, B.F. Haynes, and S.M. Alam Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions J. Virol. 83 2009 10211 10223
23. R. Diskin, J.F. Scheid, P.M. Marcovecchio, A.P. West Jr., F. Klein, H. Gao, P.N. Gnanapragasam, A. Abadir, M.S. Seaman, M.C. Nussenzweig, and P.J. Bjorkman Increasing the potency and breadth of an HIV antibody by using structure-based rational design Science (New York, NY) 334 2011 1289 1293
24. B.M. Giles, S.J. Bissel, D.R. Dealmeida, C.A. Wiley, and T.M. Ross Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines Clin. Vaccine Immunol. 19 2012 128 139
25. B.M. Giles, C.J. Crevar, D.M. Carter, S.J. Bissel, S. Schultz-Cherry, C.A. Wiley, and T.M. Ross A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect non-human primates from H5N1 infection J. Infect. Dis. 205 2012 1562 1570
26. B.M. Giles, and T.M. Ross A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets Vaccine 29 2011 3043 3054
27. J. Jardine, J.P. Julien, S. Menis, T. Ota, O. Kalyuzhniy, A. McGuire, D. Sok, P.S. Huang, S. MacPherson, M. Jones, T. Nieusma, J. Mathison, D. Baker, A.B. Ward, D.R. Burton, L. Stamatatos, D. Nemazee, I.A. Wilson, and W.R. Schief Rational HIV immunogen design to target specific germline B cell receptors Science (New York, NY) 340 2013 711 716
28. G.B. McGaughey, M. Citron, R.C. Danzeisen, R.M. Freidinger, V.M. Garsky, W.M. Hurni, J.G. Joyce, X. Liang, M. Miller, J. Shiver, and M.J. Bogusky HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb Biochemistry 42 2003 3214 3223
29. B. Mester, R. Manor, A. Mor, B. Arshava, O. Rosen, F.X. Ding, F. Naider, and J. Anglister HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D Biochemistry 48 2009 7867 7877
30. A. Mor, E. Segal, B. Mester, B. Arshava, O. Rosen, F.X. Ding, J. Russo, A. Dafni, F. Schvartzman, T. Scherf, F. Naider, and J. Anglister Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies Biochemistry 48 2009 3288 3303
31. A. Moseri, S. Tantry, Y. Sagi, B. Arshava, F. Naider, and J. Anglister An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120 Virology 401 2010 293 304
32. G. Ofek, F.J. Guenaga, W.R. Schief, J. Skinner, D. Baker, R. Wyatt, and P.D. Kwong Elicitation of structure-specific antibodies by epitope scaffolds Proc. Natl. Acad. Sci. USA 107 2010 17880 17887
33. R. Sundaram, M.P. Lynch, S.V. Rawale, Y. Sun, M. Kazanji, and P.T. Kaumaya De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies J. Biol. Chem. 279 2004 24141 24151
34. X. Wu, Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, N.S. Longo, K. McKee, S. O'Dell, M.K. Louder, D.L. Wycuff, Y. Feng, M. Nason, N. Doria-Rose, M. Connors, P.D. Kwong, M. Roederer, R.T. Wyatt, G.J. Nabel, and J.R. Mascola Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 Science (New York, NY) 329 2010 856 861
35. S.C. Harrison Viral membrane fusion Nat. Struct. Mol. Biol. 15 2008 690 698
36. R.L. Coffman, A. Sher, and R.A. Seder Vaccine adjuvants: putting innate immunity to work Immunity 33 2010 492 503
37. B. Petsch, M. Schnee, A.B. Vogel, E. Lange, B. Hoffmann, D. Voss, T. Schlake, A. Thess, K.J. Kallen, L. Stitz, and T. Kramps Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection Nat. Biotechnol. 30 2012 1210 1216
38. M. Luo, P. Tao, J. Li, S. Zhou, D. Guo, and Z. Pan Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice J. Virol. Methods 154 2008 121 127
39. K.S. Park, Y.B. Seo, J.Y. Lee, S.J. Im, S.H. Seo, M.S. Song, Y.K. Choi, and Y.C. Sung Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e Vaccine 29 2011 5481 5487
40. J.E. Ledgerwood, and B.S. Graham DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases Hum. Vaccines 5 2009 623 626
41. S. Lu Heterologous prime-boost vaccination Curr. Opin. Immunol. 21 2009 346 351
42. C.J. Wei, J.C. Boyington, P.M. McTamney, W.P. Kong, M.B. Pearce, L. Xu, H. Andersen, S. Rao, T.M. Tumpey, Z.Y. Yang, and G.J. Nabel Induction of broadly neutralizing H1N1 influenza antibodies by vaccination Science (New York, NY) 329 2010 1060 1064
43. C.J. Wei, H.M. Yassine, P.M. McTamney, J.G. Gall, J.R. Whittle, J.C. Boyington, and G.J. Nabel Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure Sci. Transl. Med. 4 2012 147ra114
44. D.R. Burton Scaffolding to build a rational vaccine design strategy Proc. Natl. Acad. Sci. USA 107 2010 17859 17860
45. J.M. Binley, E.A. Lybarger, E.T. Crooks, M.S. Seaman, E. Gray, K.L. Davis, J.M. Decker, D. Wycuff, L. Harris, N. Hawkins, B. Wood, C. Nathe, D. Richman, G.D. Tomaras, F. Bibollet-Ruche, J.E. Robinson, L. Morris, G.M. Shaw, D.C. Montefiori, and J.R. Mascola Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C J. Virol. 82 2008 11651 11668
46. N.A. Doria-Rose, R.M. Klein, M.M. Manion, S. O'Dell, A. Phogat, B. Chakrabarti, C.W. Hallahan, S.A. Migueles, J. Wrammert, R. Ahmed, M. Nason, R.T. Wyatt, J.R. Mascola, and M. Connors Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies J. Virol. 83 2009 188 199
47. A.J. Conley, M.K. Gorny, J.A. Kessler II, L.J. Boots, M. Ossorio-Castro, S. Koenig, D.W. Lineberger, E.A. Emini, C. Williams, and S. Zolla-Pazner Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D J. Virol. 68 1994 6994 7000
48. T. Muster, F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 J. Virol. 67 1993 6642 6647
49. K. Salzwedel, J.T. West, and E. Hunter A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity J. Virol. 73 1999 2469 2480
50. M.B. Zwick, R. Jensen, S. Church, M. Wang, G. Stiegler, R. Kunert, H. Katinger, and D.R. Burton Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1 J. Virol. 79 2005 1252 1261
51. J.F. Scheid, H. Mouquet, N. Feldhahn, B.D. Walker, F. Pereyra, E. Cutrell, M.S. Seaman, J.R. Mascola, R.T. Wyatt, H. Wardemann, and M.C. Nussenzweig A method for identification of HIV gp140 binding memory B cells in human blood J. Immunol. Methods 343 2009 65 67
52. G. Stiegler, R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1 AIDS Res. Hum. Retroviruses 17 2001 1757 1765
53. J. Huang, G. Ofek, L. Laub, M.K. Louder, N.A. Doria-Rose, N.S. Longo, H. Imamichi, R.T. Bailer, B. Chakrabarti, S.K. Sharma, S.M. Alam, T. Wang, Y. Yang, B. Zhang, S.A. Migueles, R. Wyatt, B.F. Haynes, P.D. Kwong, J.R. Mascola, and M. Connors Broad and potent neutralization of HIV-1 by a gp41-specific human antibody Nature 491 2012 406 412
54. L. Chen, Y.D. Kwon, T. Zhou, X. Wu, S. O'Dell, L. Cavacini, A.J. Hessell, M. Pancera, M. Tang, L. Xu, Z.Y. Yang, M.Y. Zhang, J. Arthos, D.R. Burton, D.S. Dimitrov, G.J. Nabel, M.R. Posner, J. Sodroski, R. Wyatt, J.R. Mascola, and P.D. Kwong Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120 Science (New York, NY) 326 2009 1123 1127
55. Y. Li, S. O'Dell, L.M. Walker, X. Wu, J. Guenaga, Y. Feng, S.D. Schmidt, K. McKee, M.K. Louder, J.E. Ledgerwood, B.S. Graham, B.F. Haynes, D.R. Burton, R.T. Wyatt, and J.R. Mascola Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01 J. Virol. 85 2011 8954 8967
56. J.F. Scheid, H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, A. Hurley, S. Myung, F. Boulad, P. Poignard, D.R. Burton, F. Pereyra, D.D. Ho, B.D. Walker, M.S. Seaman, P.J. Bjorkman, B.T. Chait, and M.C. Nussenzweig Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding Science (New York, NY) 333 2011 1633 1637
57. J.H. Beigel, J. Farrar, A.M. Han, F.G. Hayden, R. Hyer, M.D. de Jong, S. Lochindarat, T.K. Nguyen, T.H. Nguyen, T.H. Tran, A. Nicoll, S. Touch, and K.Y. Yuen Avian influenza A (H5N1) infection in humans New Engl. J. Med. 353 2005 1374 1385
58. I.A. Wilson, J.J. Skehel, and D.C. Wiley Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution Nature 289 1981 366 373
59. D.J. Laddy, J. Yan, N. Corbitt, D. Kobasa, G.P. Kobinger, and D.B. Weiner Immunogenicity of novel consensus-based DNA vaccines against avian influenza Vaccine 25 2007 2984 2989
60. D.J. Laddy, J. Yan, M. Kutzler, D. Kobasa, G.P. Kobinger, A.S. Khan, J. Greenhouse, N.Y. Sardesai, R. Draghia-Akli, and D.B. Weiner Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens PLoS ONE 3 2008 e2517
61. M.W. Chen, T.J. Cheng, Y. Huang, J.T. Jan, S.H. Ma, A.L. Yu, C.H. Wong, and D.D. Ho A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses Proc. Natl. Acad. Sci. USA 105 2008 13538 13543
62. R.K. Oldham, and R.O. Dillman Monoclonal antibodies in cancer therapy: 25 years of progress J. Clin. Oncol. 26 2008 1774 1777
63. Dillman Human antimouse and antiglobulin responses to monoclonal antibodies Antibody Immunoconj. Radiopharm. 3 1990 1 15
64. E. Legouffe, J. Liautard, J.P. Gaillard, J.F. Rossi, J. Wijdenes, R. Bataille, B. Klein, and J. Brochier Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6 Clin. Exp. Immunol. 98 1994 323 329
65. J. Reichert Therapeutic Monoclonal Antibodies Approved or in Review in the European Union or United States 2013 The Antibody Society Waban, Massachusetts 02468
66. B. Resch, E. Resch, and W. Muller Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour Paediatr. Respir. Rev. 14 2013 130 136
67. D. Isaacs Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against Paediatr. Respir. Rev. 14 2013 128 129
68. K. Tharakaraman, L.N. Robinson, A. Hatas, Y.L. Chen, L. Siyue, S. Raguram, V. Sasisekharan, G.N. Wogan, and R. Sasisekharan Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency Proc. Natl. Acad. Sci. USA 110 2013 E1555 E1564
69. A.T. Back, and A. Lundkvist Dengue viruses - an overview Infect. Ecol. Epidemiol. 3 2013
70. B.R. Murphy, and S.S. Whitehead Immune response to dengue virus and prospects for a vaccine Annu. Rev. Immunol. 29 2011 587 619
71. J.J. Cockburn, M.E. Navarro Sanchez, N. Fretes, A. Urvoas, I. Staropoli, C.M. Kikuti, L.L. Coffey, F. Arenzana Seisdedos, H. Bedouelle, and F.A. Rey Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody Structure (London, England: 1993) 20 2012 303 314
72. L. Simonelli, M. Pedotti, M. Beltramello, E. Livoti, L. Calzolai, F. Sallusto, A. Lanzavecchia, and L. Varani Rational engineering of a human anti-dengue antibody through experimentally validated computational docking PLoS ONE 8 2013 e55561
73. L. Simonelli, M. Beltramello, Z. Yudina, A. Macagno, L. Calzolai, and L. Varani Rapid structural characterization of human antibody-antigen complexes through experimentally validated computational docking J. Mol. Biol. 396 2010 1491 1507
74. M. Pedotti, L. Simonelli, E. Livoti, and L. Varani Computational docking of antibody-antigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin Int. J. Mol. Sci. 12 2011 226 251
75. S.S. Sidhu, and F.A. Fellouse Synthetic therapeutic antibodies Nat. Chem. Biol. 2 2006 682 688
76. A. Koide, C.W. Bailey, X. Huang, and S. Koide The fibronectin type III domain as a scaffold for novel binding proteins J. Mol. Biol. 284 1998 1141 1151
77. P. Philibert, A. Stoessel, W. Wang, A.P. Sibler, N. Bec, C. Larroque, J.G. Saven, J. Courtete, E. Weiss, and P. Martineau A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm BMC Biotechnol. 7 2007 81
78. H.L. Parsons, J.C. Earnshaw, J. Wilton, K.S. Johnson, P.A. Schueler, W. Mahoney, and J. McCafferty Directing phage selections towards specific epitopes Protein Eng. 9 1996 1043 1049
79. C.R. Geyer, J. McCafferty, S. Dubel, A.R. Bradbury, and S.S. Sidhu Recombinant antibodies and in vitro selection technologies Methods Mol. Biol. (Clifton, NJ) 901 2012 11 32
80. J. Ayriss, T. Woods, A. Bradbury, and P. Pavlik High-throughput screening of single-chain antibodies using multiplexed flow cytometry J. Proteome Res. 6 2007 1072 1082
81. J. Gao, S.S. Sidhu, and J.A. Wells Two-state selection of conformation-specific antibodies Proc. Natl. Acad. Sci. USA 106 2009 3071 3076
82. J.F. Koellhoffer, G. Chen, R.G. Sandesara, S. Bale, E.O. Saphire, K. Chandran, S.S. Sidhu, and J.R. Lai Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the Ebola virus envelope glycoprotein Chembiochem 13 2012 2549 2557
83. J.H. Kuhn, Y. Bao, S. Bavari, S. Becker, S. Bradfute, J.R. Brister, A.A. Bukreyev, Y. Cai, K. Chandran, R.A. Davey, O. Dolnik, J.M. Dye, S. Enterlein, J.P. Gonzalez, P. Formenty, A.N. Freiberg, L.E. Hensley, A.N. Honko, G.M. Ignatyev, P.B. Jahrling, K.M. Johnson, H.D. Klenk, G. Kobinger, M.G. Lackemeyer, E.M. Leroy, M.S. Lever, L.L. Lofts, E. Muhlberger, S.V. Netesov, G.G. Olinger, G. Palacios, J.L. Patterson, J.T. Paweska, L. Pitt, S.R. Radoshitzky, E.I. Ryabchikova, E.O. Saphire, A.M. Shestopalov, S.J. Smither, N.J. Sullivan, R. Swanepoel, A. Takada, J.S. Towner, G. van der Groen, V.E. Volchkov, V. Wahl-Jensen, T.K. Warren, K.L. Warfield, M. Weidmann, and S.T. Nichol Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae Arch. Virol. 158 2013 1425 1432
84. J.E. Lee, and E.O. Saphire Ebolavirus glycoprotein structure and mechanism of entry Future Virol. 4 2009 621 635
85. K. Chandran, N.J. Sullivan, U. Felbor, S.P. Whelan, and J.M. Cunningham Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection Science (New York, NY) 308 2005 1643 1645
86. M. Brecher, K.L. Schornberg, S.E. Delos, M.L. Fusco, E.O. Saphire, and J.M. White Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change J. Virol. 86 2012 364 372
87. J.E. Carette, M. Raaben, A.C. Wong, A.S. Herbert, G. Obernosterer, N. Mulherkar, A.I. Kuehne, P.J. Kranzusch, A.M. Griffin, G. Ruthel, P. Dal Cin, J.M. Dye, S.P. Whelan, K. Chandran, and T.R. Brummelkamp Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 Nature 477 2011 340 343
88. J.E. Lee, and E.O. Saphire Neutralizing Ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it Curr. Opin. Struct. Biol. 19 2009 408 417
89. G.S. Mohan, W. Li, L. Ye, R.W. Compans, and C. Yang Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus PLoS Pathog. 8 2012 e1003065
90. C.F. Basler A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein Expert Rev. Anti Infect. Ther. 11 2013 475 478
91. O. Dolnik, V. Volchkova, W. Garten, C. Carbonnelle, S. Becker, J. Kahnt, U. Stroher, H.D. Klenk, and V. Volchkov Ectodomain shedding of the glycoprotein GP of Ebola virus EMBO J. 23 2004 2175 2184
92. H. Persson, W. Ye, A. Wernimont, J.J. Adams, A. Koide, S. Koide, R. Lam, and S.S. Sidhu CDR-H3 diversity is not required for antigen recognition by synthetic antibodies J. Mol. Biol. 425 2013 803 811
93. S. Koide, and S.S. Sidhu The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins ACS Chem. Biol. 4 2009 325 334